


EurobioPlex SARS-CoV-2 SNPs

RT-PCR for qualitative identification¹
of SARS-CoV-2 and mutations

SCREENING AND TYPING



MADE BY
EUROBIO
SCIENTIFIC
IN FRANCE

Result in 1h30

Detection and identification in 1 well with endogenous Ct²

1. For more information, please refer to the paragraph "Slide destination" in the user manual.
2. For more information, please refer to the "Principle" section of the instruction manual.
3. For more information, please refer to the "Protocol" section of the instruction manual.

22/06/2021



CLINICAL CONTEXT

SARS-CoV-2 virus appeared in China in late 2019, in the city of Wuhan. It belongs to the Coronaviridae family and to the Sarbecovirus subgenus. From this pathology, many variants have emerged including three mutations, named E484K, E484Q and L452R. These mutations are common to a variety of variants and are associated with possible increased transmissibility (L452R) or immune escape (L452R, E484K and E484Q).⁴

The clinical picture is can vary : from asymptomatic patients to those evoking an unspecific cold (fever, cough, fatigue...). In some cases, the symptoms will evolve rapidly and unfavorably with breathing difficulties, pneumonia, and sometimes a severe respiratory syndrome that can be fatal.⁵

DIAGNOSIS

The diagnosis of SARS-CoV-2 infection is nowadays exclusively based on the detection of viral particle by RT-PCR.

Rapid antigen testing is an additional tool to reduce viral transmission chains. This antigen test determines whether the person is infected at the time of testing and is primarily reserved for symptomatic persons. Serological tests (TROD) are used to investigate whether a person has developed an immune response after contact with the virus.⁶

CHARACTERISTICS

Principle of the test	Detection of the SARS-Cov-2 pathogen and its mutations
Technology	Real Time RT-PCR
Targetgenes ²	SARS CoV-2 RdRp1 and RdRp2 genes; E484K, E484Q, L452R mutations
Type of samples ¹	Nasopharyngeal swabs
Controls included ³	Positive, negative and internal controls
Time to result	<1h30 ³
Thermocyclers ⁷	Validated on CFX96 [®]

PERFORMANCES

Sensitivity⁸

> 99%

Specificity⁸

> 99%

Detection threshold⁸ : depending on the target.

Reference	Description	Packaging
EBX-046	EurobioPlex SARS-CoV-2 SNPs PCR in real time	48/96/192 tests

4. Santé Publique France .2021. Circulation of variants: a new strategy for screening by searching for mutations of interest.[2021/06/10].

Circulation des variants: nouvelle stratégie de criblage par la recherche de mutations d'intérêt (santepubliquefrance.fr)

5. For more information, please refer to the "General Information" section of the instruction manual.

6. Institut Pasteur.2021.COVID-19 DISEASE (NEW CORONAVIRUS). [2021/01/13].

Maladie Covid-19 (nouveau coronavirus) | Institut Pasteur.

7. For more information, please refer to the "Real-time PCR Instrument" section of the instruction manual.

8. For more information, please refer to the "Performance Analysis" section of the instruction manual.